Novaliq’s NovaTears® Treatment for Evaporative Dry Eye Disease Launches in New Zealand and Receives Registrational Approval in Australia
Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced the launch of NovaTears® in New Zealand and registrational approval in Australia.
According to McCarty, the prevalence of dry eye disease (DED) is approximately 7.4 percent in Australia and New Zealand; counting for more than 2 million people suffering from dry eye disease in this region1.
In March 2017, Novaliq and AFT Pharmaceuticals (AFT) signed an exclusive licensing partnership agreement for the commercialization of NovaTears® across Australasia. AFT Pharmaceuticals Ltd (AFT), a New Zealand-based pharmaceutical company listed on ASX and NZX, will commercialize NovaTears®, the first and only water-free topical eye drop treatment specifically developed to treat patients with DED. According to the latest TFOS DEWS II definition and classification report2, patients with tear-lipid dysfunction account for the greater proportion of all DED patients and no adequate treatment option was available in New Zealand until now.
NovaTears® immediately stabilizes the lipid layer without causing vision blurring. Clinically validated in four clinical trials, NovaTears® eye drops are proven to be safe and effective. Results from these trials showed that NovaTears® is safe and efficacious for treating the signs and symptoms of DED and Meibomian Gland Dysfunction (MGD). A large number of objective disease parameters such as tear film breakup time, corneal and conjunctival fluorescein staining but also a number of expressible Meibomian glands and Meibom quality have been improved under NovaTears® treatment.
“NovaTears® is a first-in-class treatment for this common and highly underserved ophthalmic disease,” said Christian Roesky, PhD, managing director and CEO, Novaliq GmbH. “NovaTears® is a clinically validated treatment that significantly improves signs and symptoms of patients suffering from dry eye disease. We know from our clinical studies that NovaTears® immediately stabilizes the lipid layer and restores the natural tear film of the eye over time. I am confident that dry eye patients in Australasia will greatly benefit from this breakthrough innovation.”
For patients, NovaTears® eye drops combine high efficacy with great comfort. Signs and subjective symptoms of DED are significantly reduced without causing blurry vision after application. NovaTears® is pure, and therefore has no side effects related to preservatives or other additives.
For healthcare professionals, NovaTears® expands the established treatment portfolio with a new option of a water-free formulation and a new mode of action to treat more patients effectively. NovaTears® increases patients’ compliance due to proven clinical effectiveness and tolerability.
“We are thrilled to be able to offer patients a novel ophthalmic treatment that addresses signs and symptoms of evaporative DED and MGD,” said Hartley Atkinson, PhD, CEO, AFT. “NovaTears® is a first-in-class, water-free and preservative-free treatment that strengthens the lipid layer of the tear film thereby preventing evaporation. It is a welcome addition to our eye care line, one that will provide superior benefits to patients.”
About Novaliq – Novaliq GmbH, founded in 2007, is a Heidelberg based specialty pharmaceutical company focused on ophthalmology. Its mission is to transform poorly soluble drugs into effective ocular therapeutics for both the front and the back of the eye. Novaliq’s proprietary EyeSol® technology enhances the topical bio-availability, stability and safety of traditionally insoluble or unstable drugs improving the delivery, efficacy and convenience of treatments for ocular surface diseases including dry eye through preservative free and multi dose formulations. Novaliq has developed a tiered and long-term sustainable dry eye family of truly differentiated products that addresses the different needs of dry eye patients. Novaliq’s most advanced product is NovaTears® with CE-approval marketed under the brand name EvoTears® in Europe. CyclASol® a second-generation prescription drug is currently in preparation for a pivotal trial. More on www.novaliq.com.
About AFT Pharmaceuticals – AFT founded in 1997 is an Auckland, New Zealand-based pharmaceuticals company operating in Australia, New Zealand and the Pacific Islands. AFT has been listed on the Australian [ASX] and New Zealand [NZX] stock exchanges since December 2015 and has significant local sales operations in Australasia together with R&D activities in pain, orphan drugs and medical devices.
1. McCarty CA, Bansal AK, Livingston PM, Stanislavsky YL, Taylor HR. The
epidemiology of dry eye in Melbourne, Australia. Ophthalmology
2. TFOS DEWS II Definition and Classification Report 2017
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Andersen Global Initiates Expansion in Mozambique14.8.2018 13:30 | Pressemelding
Andersen Global continues expansion in Africa with Isalcio Mahanjane e Associados, a law firm headquartered in Maputo, Mozambique. The collaboration with Isalcio Mahanjane e Associados signifies Andersen’s growth in the African region, as Mozambique provides strategic coverage in Southeast Africa and is the sixth country to collaborate or join in Africa in the past 14 months. Led by Managing Partner Isalcio Mahanjane, the firm includes 10 professionals and specializes in providing quality services in all branches of law for corporations and individuals. These services include commercial and corporate law, banking and financial law, labor law, real estate management, oil and gas, mines, and law and administrative litigation. “Mozambique will be a key point of connectivity with our practice in Portugal as we continue to focus on best-in-class solutions in Africa,” commented Global Chairman and Andersen Tax LLC CEO, Mark Vorsatz. “Isalcio and his team are passionate about their practice a
Gyeonggi Province of Korea Launches Beyond the Dream Global VLOG Contest14.8.2018 12:00 | Pressemelding
Gyeonggi Provincial Government and Gyeonggi Tourism Organization (GTO) are hosting an international video contest called “Beyond the Dream VLOG Contest 2018.” Video submissions will be accepted until August 26, 2018 (Korean Standard Time). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180814005240/en/ Gyeonggi Provincial Government and Gyeonggi Tourism Organization (GTO) are hosting an international video contest called "Beyond the Dream VLOG Contest 2018." Video submissions will be accepted until August 26, 2018 (Korean Standard Time). The goal of the "Beyond the Dream VLOG Contest 2018" is to raise global awareness of Gyeonggi Province as an attractive travel destination and to select a Gyeonggi-do tourism ambassador who will show the world the charms of the province. Four final-winning teams will win a 10 day trip to Gyeonggi Province. USD 10,000 travel expenses for airline tickets and other travel expenses will be provi
CTS Engines Inducts First PW2000 Engine14.8.2018 12:00 | Pressemelding
CTS Engines, the global leader for mature engine maintenance within the Aerospace & Defense industry, announced today that it had inducted the first PW2000 engine into its engine overhaul facility in Ft. Lauderdale, FL. Along with the CF6-80C2, CF6-80A, and CF6-50C2, the PW2000 represents the fourth engine model type serviced by CTS. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180814005021/en/ PW2000 Engine. (Photo: Business Wire) “The profile of the PW2000 engine—which will continue to operate on B757s in cargo configuration and on C-17 Globemaster military transport aircraft for years to come—is an ideal fit for the CTS product line,” said Vesa Paukkeri, CTS’s President and Chief Operating Officer. “CTS is the go-to independent jet engine MRO for sunset engines operating in cargo and military transport configurations. We look forward to servicing this engine through the remainder of its time on wing over the next 30+ ye
BOC Group has just released ADONIS:CE – A Milestone in Free Cloud BPM Tools!14.8.2018 11:00 | Pressemelding
BOC Group announces the release of brand new ADONIS:Community Edition, now available in the cloud for free. Today, BOC Group launched the next in line descendent of its worldwide-known free Business Process Management tool, ADONIS:CE. This launch is more than just a product update: it marks the ADONIS:Community Edition's shift to the battle-tested web-platform and its transition to the cloud as SaaS. Based on the latest version of BPM suite's commercial edition ADONIS NP 5.5, ADONIS:CE makes a grand entrance with its fresh design, state-of-the-art functionality and exceptional user experience. Tobias Rausch, ADONIS product manager elaborates: “We believe in spreading BPM to all regions, as well as teams and companies of all sizes, by providing a free-of-charge tool that helps businesses improve their process game. That is why we have designed a freely available BPM tool with such an outstanding and rich feature-set.” In addition to the capabilities mentioned above, ADONIS:CE comes with
Interxion Announces Direct Connectivity to Google Cloud Platform across Its European Footprint14.8.2018 08:00 | Pressemelding
INTERXION HOLDING NV (NYSE: INXN), a leading provider of carrier and cloud-neutral colocation data centre services in Europe, today announced that dedicated access to Google Cloud Platform (GCP) is now available across its European footprint through Cloud Connect, Interxion’s multi-cloud interconnection platform. With Google Cloud deploying its Cloud Interconnect points of presence (PoPs) in Interxion’s Paris, Marseille, Frankfurt and Stockholm data centres, customers can now directly connect to Google Cloud Platform from these locations. Moreover, because Interxion is a partner of Google Cloud’s newly launched Partner Interconnect service, customers can also connect from any of Interxion’s data centres across Europe via Cloud Connect. Customers using this service benefit from fully redundant, instant access to GCP from multiple metropolitan areas, ensuring a 99.99% availability SLA without the complexity and costs of having to build a networking solution themselves. “We are seeing str
Lumileds Wins Jury Verdict of Liability for Intellectual Property Theft Against Elec-Tech International Co., Ltd., Donglei Wang, and Gangyi Chen13.8.2018 22:45 | Pressemelding
On August 10, 2018, a jury of six men and six women rendered a verdict in favor of one the world’s leading LED companies, Lumileds LLC, based in San Jose, finding that a Chinese competitor stole trade secrets related to Lumileds core technology for making high power LEDs used in flash phones, automotive headlights, and general illumination. The case, Lumileds LLC v. Elec-Tech International Co., Ltd., Donglei “Tony” Wang, and Gangyi Chen, Superior Court of the State of California, County of Santa Clara, found the defendants liable for damages in intellectual property theft. The jury awarded Lumileds $66 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180813005694/en/ Mark Adams, Chief Executive Officer at Lumileds Inc. (Photo: Business Wire) The jury concluded that ETI, Wang and Chen misappropriated Lumileds trade secrets, took them to China, and used them to develop ETI’s LED technology. The award of $66 million is t